BerGenBio gets funding for combo trial in advanced lung cancer
Norwegian clinical-stage biotech firm BerGenBio has been awarded a 24 million Norwegian kroner ($2.85 million) grant from Innovasjon Norge to support the clinical development of its BGB324 in combination with US pharma giant Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) in patients with advanced lung cancer.
BerGenBio will sponsor a Phase II study multicenter study of BGB324, which since 2014 has US Food and Drug Administration orphan states for the treatment of acute myeloid leukemia (AML), in combination with Keytruda in patients with previously treated unresectable adenocarcinoma of the lung.
In March this year, BerGenBio entered into a collaborative agreement with Merck focused on the clinical evaluation of BGB324 with Keytruda in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze